Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 60 % of short-term debt in 2025; threshold 65 %.
-
Figures corrected NBB
Corrected annual account filed for 2024.
Financials
Financial year 2025
KEYPHARM from Oostkamp, company number BE0883397311, closed financial year 2025 with a result of € 1.6 million after tax. For that financial year KEYPHARM recorded revenue of € 14.9 million and equity of € 5.2 million. Compared with financial year 2024, the result moved from € 990,366 to € 1.6 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 10, 2026.
€ 5.2 million
▲ 15% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 1.6 million
▲ 58% vs 2024
Profit after tax over the fiscal year.
€ 57,871
▼ 38% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 896,000 paid out
57 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
18
▲ 0.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.4 million
▲ 3% vs 2024
€ 75,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 55,911
▼ 22% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 1.3 million
▲ 19% vs 2024
€ 165,503 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 1.9 million
▼ 3% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 56 days on average.
€ 196,945
▼ 7% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 11,417,354 | € 12,392,526 | € 13,488,668 | € 14,877,926 | ▲ 10% |
| Profit after taxes | € 825,489 | € 802,767 | € 990,366 | € 1,564,433 | ▲ 58% |
| Equity | € 3,847,537 | € 4,130,304 | € 4,533,670 | € 5,202,102 | ▲ 15% |
| Total debts | € 3,672,451 | € 3,996,936 | € 4,012,626 | € 4,284,021 | ▲ 7% |
| Cash | € 127,673 | € 188,111 | € 93,587 | € 57,871 | ▼ 38% |
| Retained profit | € 3,047,537 | € 3,330,304 | € 3,733,670 | € 4,402,102 | ▲ 18% |
| Dividend | € 368,000 | € 520,000 | € 587,000 | € 896,000 | ▲ 53% |
| Bank debt | € 1,598,852 | € 1,283,454 | € 1,082,787 | € 1,293,858 | ▲ 19% |
| Balance sheet total | € 7,519,987 | € 8,127,239 | € 8,546,295 | € 9,486,123 | ▲ 11% |
| Employees (FTE) | 17.1 | 18.1 | 17.9 | 18 | ▲ 0.1 |
Key figures of KEYPHARM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to KEYPHARM?
What happened at KEYPHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Rias Baixas BV stepped down as director. NBB
- Corujo BV stepped down as director. NBB
- Manipuro BV stepped down as director. NBB
- Melissa Hellebuyck stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 1.6 million (▲ 58% vs 2024). Source: NBB ↗
- Rias Baixas BV became a director. NBB
- Corujo BV became a director. NBB
- Manipuro BV became a director. NBB
In short
From € 825,489 profit in 2022 to € 1.6 million profit in 2025.
Paid € 759,333 in corporate taxes since 2022.
Best year ever: 2025, with € 1.6 million profit.
Paid out € 2.4 million in dividends to the owners in total.
A new publication or filing at KEYPHARM? We notify you, reason included.
Follow KEYPHARMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2025 annual accounts
since 2022 · until 2028
since 2022 · until 2028
since 2022 · until 2028
since 2022 · until 2028
Establishments
Establishment units
Physical locations of this company
Siemenslaan 11
8020 Oostkamp
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
COMBELL-AS, BE
Domain
Domain
keypharm.com
Registered
2009-03-06
Registrar
Ascio Technologies, Inc. Danmark - Filial af Ascio technologies, Inc. USA
Expires
2027-03-06
Website info
Features
Security
Network
Details
- Company number
- 0883.397.311
- VAT number
- BE 0883.397.311
- Registered office
- Siemenslaan 11, 8020 Oostkamp
- Names & denominations
- KEYPHARM
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 8 September 2006
- Peppol
- Active · Active since 29 Oct 2025
- Contact
- keypharm.com
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsvoering en beheer
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering